FDA Approves New Drug for Type 2 Diabetes

In early May 2011, the U.S. Food and Drug Administration (FDA) approved the use of linagliptin to improve blood sugar control in adult patients with type 2 diabetes. In this case, linagliptin can be used as single drug or in combination with other therapies. Linagliptin, which is available in tablet form, works by increasing levels of hormones that stimulate insulin release after meals by blocking the enzyme activity dipeptidil peptidase-4.In early May 2011, the U.S. Food and Drug Administration (FDA) approved the use of linagliptin to improve blood sugar control in adult patients with type 2 diabetes. In this case, linagliptin can be used as single drug or in combination with other therapies. Linagliptin, which is available in tablet form, works by increasing levels of hormones that stimulate insulin release after meals by blocking the enzyme activity dipeptidil peptidase-4.


Results from eight double-blind clinical trials with placebo comparison showed that the drug is safe and effective for persons with type 2 diabetes. Linagliptin already been investigated as a single agent or in combination with other type 2 diabetes therapy, such as Metformin, Glimepiride, and pioglitazone. However, the combination linagliptin and insulin have not been investigated.

Clinicians should not prescribe linagliptin for persons with type 1 diabetes or for those who experience diabetic ketoacidosis. The most common side effects include upper respiratory tract infection, nasal congestion or runny nose, sore throat, muscle aches, and headaches.
kalbe.co.id